ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
British pharmaceuticals major GlaxoSmithKline says it is shedding almost 200 jobs at its site in Ulverston, England, involved in the manufacture of active ingredients for sterile injections. GSK aims to make the job cuts by 2020. The move follows a 2017 review of its U.K. operations to improve the efficiency and competitiveness of its manufacturing network. The company says it will retain about 150 at the Ulverston site to produce cephalosporin antibiotics, a business the firm says is enjoying strong growth.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter